News
Article
Author(s):
Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 diabetes patients.
In a head-to-head trial Lilly’s GLP-1 dual agonist demonstrated the ability to protect against cardiovascular events.
Stock.adobe.com
Eli Lilly and Company announced the results from SURPASS-CVOT, a head-to-head Phase III cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes as well as established atherosclerotic cardiovascular disease. SURPASS-CVOT enrolled upwards of 13,000 participants across 30 countries, with trials spanning over four and a half years.
Lilly’s Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, was tested alongside Trulicity (dulaglutide), a GLP-1 receptor agonist showing definitive cardiovascular benefits in its REWIND study. During SURPASS-CVOT, Mounjaro reached its primary objective of demonstrating a non-inferior rate of major adverse cardiovascular events (MACE-3), including cardiovascular death, heart attack, and stroke while directly competing against Trulicity. Under a non-controlled environment for multiplicity-adjusted type-1 errors, Mounjaro portrayed improvements on critical measures of A1C weight, renal function, and all-cause mortality.
Kenneth Custer, Ph.D., executive vice president and president of Lilly cardiometabolic health mentioned the results of SURPASS-CVOT, saying, "Cardiovascular disease remains the leading cause of death among people living with type 2 diabetes, the SURPASS-CVOT results show that Mounjaro preserved the cardioprotective benefit of Trulicity, a GLP-1 receptor agonist while providing additional benefits, including greater kidney protection and a reduced overall risk of death. These findings strengthen the case for Mounjaro as a potential front-line treatment for people with type 2 diabetes and cardiovascular disease."1
Mounjaro’s performance in the SURPASS-CVOT trials demonstrated the treatment’s capabilities, specifically providing patients an 8% reduction for risks of cardiovascular death, heart attack, and stroke when compared to Trulicity. These results provided Mounjaro the criteria of non-inferiority, while also displaying consistent results for all three MACE-3 components.
An indirect comparison of the SURPASS-CVOT and REWIND studies allocated Mounjaro to exhibit the following results:
Mounjaro and Trulicity both tested consistently within their established profiles for safety and tolerability, with the most reported adverse events for both being gastrointestinal-related. The adverse effects were resolved following the completion of dose escalation but following testing, a reported 13.3% of participants ceased Mounjaro treatments compared to 10.2% of Trulicity users.
The trial results for Mounjaro reaffirmed its established background in benefits for patients suffering from heart disease and type 2 diabetes, while also providing critical new data to assist in advancing developments for the medicine.
The results of SURPASS-CVOT are expected to be presented at the European Association for the Study of Diabetes annual meeting taking place in September this year. Results will also be published in a peer-reviewed journal while Lilly will submit the data to global regulatory authorities by years end.
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
